Generic API

Generic API

Bilim Pharmaceuticals is a prominent international supplier of Generic Active Pharmaceutical Ingredients (APIs), expertly manufacturing products through advanced chemical and biological synthesis. Located in the heart of Istanbul, Turkey, we boast a robust portfolio of over 300 generic APIs and manage upwards of 450 Drug Master Files worldwide, covering major therapeutic areas such as oncology, CNS, infectious diseases, immunology, dermatology, cardiovascular, and many others.

Our commitment to leveraging the latest technology and processes, coupled with our extensive analytical capabilities, positions us as a competitive partner in enhancing market readiness and competitiveness. We have made strategic investments across several production lines and facilities, enabling us to handle a diverse range of high-containment molecules at various scales and offering unparalleled flexibility.

Bilim Pharmaceuticals provides comprehensive in-house analytical testing services, delivering both time and cost efficiencies to our clients. Our leading-edge technologies and expertise in chemistry and biotechnology make us a versatile and agile API provider, meeting the exacting demands of both generic and innovative pharmaceutical industries.

We tailor our APIs to meet specific chemical and physical project requirements, ensuring compliance with stringent quality and regulatory standards. This positions Bilim Pharmaceuticals as a trusted partner in navigating complex approval processes from the world’s most demanding regulatory authorities.

Bilim Pharmaceuticals: Pioneering Retinoid and Respiratory Solutions

 

At Bilim Pharmaceuticals, we have established ourselves as a market leader in the retinoid sector, boasting a comprehensive portfolio that encompasses all key active ingredients such as Tretinoin, Etretinate, Fenretinide, Isotretinoin, Alitretinoin, Tazarotene, Acitretin, and Trifarotene. Our commitment to innovation extends to the respiratory sector, where we have significantly enhanced our offering of active ingredients. This expansion is driven by our dedication to addressing unmet needs in niche therapeutic areas and our development of molecules with specialized physical properties for use in state-of-the-art inhalers.

In line with recent advancements, we have introduced several novel New Chemical Entities (NCEs) utilizing proprietary technologies and backed by patent filings. Our facilities are fully licensed for the commercial importation and processing of narcotic raw materials, enabling us to manufacture and globally distribute a range of controlled substances, including psychotropics and intermediate lysergic acid. We currently hold licenses for Schedule III and IV APIs, including Diethylpropion HCl, Phendimetrazine Tartrate, Phentermine HCl, and Benzphetamine HCl.

Looking forward, Bilim Pharmaceuticals is set to delve into Antibody-Drug Conjugates (ADCs), representing a significant frontier in the generic pharmaceutical market. This move is expected to substantially elevate our complexity and expertise. Our strategic focus on enhancing our generic drug pipeline is aligned with our commitment to the sustainability of global healthcare systems, ensuring the introduction and affordability of essential therapies worldwide.